Last reviewed · How we verify
RPV-LA Maintenance Dose
RPV-LA Maintenance Dose is a long-acting formulation of rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the replication of HIV-1.
RPV-LA Maintenance Dose is a long-acting formulation of rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the replication of HIV-1. Used for Treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.
At a glance
| Generic name | RPV-LA Maintenance Dose |
|---|---|
| Also known as | Rilpivirine Long-Acting Injectable |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Target | HIV-1 reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Rilpivirine binds to the HIV-1 reverse transcriptase enzyme, preventing the conversion of viral RNA into DNA. This action inhibits the replication of the virus, thereby reducing the viral load in the body.
Approved indications
- Treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older
Common side effects
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)
- A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 (PHASE3)
- Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study
- The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE (PHASE3)
- Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study (PHASE3)
- Improving HIV-1 Control in Africa with Long Acting Antiretrovirals (PHASE3)
- A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: